Each IMAZOLE-V Pessary contains:
Clotrimazole B.P: 100mg
In a special water soluble base.

IMAZOLE-V contains clotrimazole, a new generation imidazole derivative possessing a potent and broad spectrum antifungal, anticandidal and antitrichomonal activity. In vitro, depending on the concentration , clotrimazole exhibits fungistatic or fungicidal activity against a wide range of isolates of Deratophytes e.g Trichophyton rubrum, Trichophyton mentagrophyte, Epidermatophyton floccosum. Clotrimazole exhibits a high degree of anticandidal action on pathogenic strains of Candida e.g Candida albicans; it also shows a good antimicrobial action on Malassezia furfur. Strains of fungi having a natural resistance to clotrimazole are rare. No single step or multiple step resistance to clotrimazole has developed during successive passages of Candida albicans. Clotrimazole is known to possess antitrichomonal and antibacterial activity particularly against some of the gram positive organisms. Clotrimazole causes alteration in the cell wall permeability and leads to leakage of intracellular phosphorus compounds with concomitant breakdown of cellular nucleic acid and accelerated potassium influx. These rapidly and extensively developing changes contribute to fungicidal activity of clotrimazole. Following the topical or vaginal administration clotrimazole appears to be minimally absorbed.

IMAZOLE-V is usually well tolerated when used in the recommended dose. As clotrimazole is not absorbed through the vaginal mucosa, IMAZOLE-V is unlikely to produce any systematic side effects. Occasionally, IMAZOLE-V may lead to local side effects e.g burning or irritation. These symptoms usually tend to subside and need no withdrawal of the therapy. However, if irritation or burning is of severe nature or persists then it is advisable to discontinue the treatment. IMAZOLE-V pessaries being colourless do not stain the underwear.

The usual recommended dose of IMAZOLE-V is one pessary to be inserted deep into the vagina, preferably when lying on the back, for seven consecutive nights before retiring. In case of a refractory or recurring infection the dose and/or duration may be doubled. For better results, the treatment should be commenced after menstruation or completed before the start of menstruation.

Due to lack of data, the use of IMAZOLE-V, during first trimester should be avoided, if possible. However, use of clotrimazole in second and third trimesters of pregnancy appears to be not associated with ill effects. Considering that candidosis is common in late pregnancy period, and IMAZOLE-V is non-systematic in action, Imazole V may be used in the last weeks of pregnancy if thought to be beneficial.